查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863392

急性护理综合症检测市场：按综合征检测组合、产品类型、最终用户、技术和应用划分 - 全球预测（2025-2032 年）

Acute Care Syndromic Testing Market by Syndromic Panel, Product Type, End User, Technology, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，急性照护中的症候群检测市场将成长至 81.9 亿美元，复合年增长率为 10.27%。

关键市场统计数据
基准年 2024 37.4亿美元
预计年份：2025年 41.2亿美元
预测年份 2032 81.9亿美元
复合年增长率 (%) 10.27%

简明扼要地介绍了急性护理中综合征检测的模式转移，重点说明临床整合、诊断速度和系统弹性。

在技​​术进步、临床工作流程变革以及对诊断速度和准确性日益增长的期望的推动下，急性护理中的综合征检测领域正经历着快速且持续的演变。能够同时检测多种病原体的综合征检测正越来越多地应用于急诊和住院环境中，因为在这些环境中，时间紧迫的决策对患者预后至关重要。随着临床团队寻求缩短诊断时间并减少对经验性治疗的依赖，能够与诊疗路径无缝衔接的诊断平台正从概念验证阶段走向实际应用阶段。

此外，实验室基础设施与照护现场能力之间的交互作用正在重塑采购重点。医疗机构管理者需要在高通量集中检测与能够在床边提供可操作结果的分散式解决方案之间寻求平衡。同时，公共卫生部门和感染预防团队正在利用症状数据进行监测和疫情应对，这进一步凸显了诊断在更广泛的人口健康策略中的作用。因此，临床、营运和商业等各部门的相关人员必须在预算有限的情况下，通力合作，以证明其在实际应用中的表现、互通性和临床效用。

技术、监管和医疗服务模式的变革正在重塑综合征检测路径，并加速医疗机构采用照护现场诊断技术。

变革性的变化正在汇聚，重新定义急性护理环境中综合征检测的开发、部署和维护方式。包括高通量多重检测、整合式样本到结果平台以及先进的资料管理功能在内的技术创新，正在降低快速诊断的门槛。这些技术与检测设计的改进相辅相成，在保持分析灵敏度和特异性的同时，拓宽了病原体检测范围，并将临床应用场景从传统的呼吸道病原体检测扩展到神经系统、消化器官系统和性行为感染感染等领域。

同时，医疗服务模式也在不断调整。急诊室、加护病房和门诊急诊中心都要求更快的检测结果和更简化的工作流程，以减少对专业实验室技术人员的依赖。监管环境和报销机制也在不断发展，鼓励在能够透过治疗效果、抗菌药物管理和缩短住院时间来证明其临床价值的情况下，加快相关检测方法的应用。此外，数位化连接和分析技术使得近乎即时地汇总综合征检测结果成为可能，从而为加强医疗监测和跨机构公共卫生讯号检测创造了机会。这些变化共同作用，正迅速将综合征检测从一种小众的诊断辅助手段转变为急性期医疗管理的重要组成部分。

评估2025年美国关税调整对供应链、医疗设备采购、生产奖励和临床营运的多面向影响

2025年美国关税政策调整为参与综合症检测的製造商、经销商和医疗保健机构带来了新的挑战。由于进口成本上升和前置作业时间不确定性，原本以即时库存管理为优化策略的供应链被迫重新评估筹资策略。为此，许多医疗设备和试剂供应商加快了供应商网路的多元化，并探索区域性生产和组装方案，以降低进口波动带来的风险。

因此，医院和检测实验室的采购部门在供应商风险评估方面变得更加严格，并优先考虑能够提供更高生产能力和紧急时应对计画透明度的长期供应协议。对于平台製造商而言，关税环境促使他们重新评估定价结构和总体拥有成本 (TCO) 模型，这些模型考虑了物流、海关延误和库存持有成本。随着时间的推移，这些调整影响了产品蓝图和资本分配决策，推动了对模组化设计和可互换耗材的投资，从而减少了对单一来源组件的依赖。

重点，前置作业时间的不确定性影响了高需求检测试剂套件的供应，为临床操作带来了过渡期的摩擦。为应对这项挑战，实验室扩大了替代检测方法的检验，加强了与临床相关人员的合作，并根据病情严重程度和感染控制需求确定了检测的优先顺序。儘管产业透过这些调整展现了韧性，但关税造成的衝击凸显了供应链透明度、生产灵活性和积极主动的相关人员沟通的战略重要性。

深入的細項分析揭示了小组、产品类型、最终用户、技术和应用如何驱动急诊护理领域的采用模式和采购决策。

深入了解市场区隔动态对于理解需求领域和不断变化的采购选择至关重要。在考虑综合征检测组合时，由于神经系统感染疾病的严重性，中枢神经系统（脑炎/脑膜炎亚群）类别优先考虑高分析灵敏度和快速出结果。区分细菌、寄生虫和病毒病原体的胃肠道检测组合需要强大的多重检测能力和广泛的检体相容性。根据细菌、混合和病毒标靶分類的呼吸道检测组合需要在检测广度和通量之间取得平衡，以应对季节性需求高峰。针对披衣菌感染、淋病和疱疹的性行为感染检测组合需要针对多种检体类型进行最佳化且具有高特异性的检测方法。

从产品类型角度来看，从桌上型分析仪到照护现场设备等各类设备组合，直接影响资本支出规划与实验室空间决策。同时，套件和试剂（包括试剂盒、多重检测套组和单组分试剂）则支撑持续的收入来源和供应保障。专注于资料管理和服务合约的软体和服务，在长期总成本和营运效率方面正发挥着日益重要的作用。最终用户细分决定了采用路径：学术机构优先考虑检测的灵活性和深度，以支援转化研究；医院需要检验的工作流程和快速的临床报告；公共卫生实验室重视监测相容性和高通量能力；而参考实验室则专注于规模和多重检测，以服务庞大的客户网络。技术选择也影响策略：质谱、微阵列、多重PCR、次世代定序和qPCR等技术在通量、广度和周转时间方面各有优劣。最后，诸如鑑别诊断、流行病学、疫情调查、监测和监控等应用领域决定了性能要求以及与临床和公共卫生资讯系统的整合程度。总而言之，这些细分维度指导着采购优先顺序、检验策略和相关人员伙伴关係模式。

影响美洲、欧洲、中东和非洲以及亚太地区症候群检测计画实施和支持的区域趋势和战略考量

区域趋势对综合征检测项目的部署策略、监管协调和配套基础设施有显着影响。在美洲，就地检验的普及和电子健康记录互联互通的奖励正在推动医院和门诊机构采用该技术，而区域供应链中心和生产能力则支持快速补货。在欧洲、中东和非洲地区，不同的法规结构和不均衡的报销环境要求差异化的商业化策略和客製化服务模式，以适应实验室整合和集中化的趋势。在亚太地区，产能的快速扩张、对本地生产的投资以及对强有力的公共卫生监测的重视，正在加速高通量和分散式平台的普及。

这些区域差异不仅影响技术的部署地点，也影响企业如何建立其市场推广和售后支援体系。例如，在本地技术专长有限的地区，服务协议和本地技术支援至关重要；而拥有先进数位健康基础设施的系统则优先考虑软体互通性和资料共用标准。此外，采购週期和资金分配因地区而异，这会影响新面板的采用速度和平台升级。了解这些地域差异有助于负责人将分销策略、本地伙伴关係和培训计划与当地的预期和营运实际情况相匹配。

竞争格局和企业策略塑造了急性护理综合症检测生态系统中的创新、伙伴关係和商业化。

在综合征检测生态系统中，各公司的策略正沿着多个维度发展，包括平台差异化、垂直耗材整合以及与实验室网路和医疗保健系统的策略联盟。製造商致力于提供端到端解决方案，以最大限度地缩短操作时间、减少故障点，并与实验室资讯系统和电子健康记录无缝连接。同时，各公司也投资开发能够带来持续收入的耗材产品组合，并采用模组化设计设备，以避免客户面临设备过时的风险。

伙伴关係与联盟模式正逐渐成为加速市场渗透和检验产品在不同医疗环境中临床效用的重要手段。企业越来越多地与学术机构合作进行临床检验研究，并与公共卫生机构合作，以统一报告格式和监测应用情境。快速反应的技术支援和库存管理等服务模式也在影响市场竞争，并成为采购决策中的差异化因素。总体而言，市场将青睐那些能够将强大的分析能力与完善的售后支援、清晰的整合路径以及灵活的商业条款相结合，从而满足不同终端用户需求的企业。

为产业领导者提供切实可行的策略建议，以优化供应链韧性、加速临床应用，并使商业模式与医疗保健优先事项保持一致。

寻求获得可持续竞争优势的行业领导者应优先考虑一系列综合倡议，涵盖技术、供应链、临床实施和商业性诚信。首先，投资于平台互通性和开放资料标准将加速临床整合，并支援下游分析以展现价值。其次，实现製造和物流合作伙伴多元化，并开发区域分销方案，将最大限度地减少贸易中断和海关波动对营运的影响。第三，透过真实世界证据研究和以管理为重点的试点项目，将临床证据的生成融入商业部署，将推动应用并加强与支付方的对话。

此外，经营团队应考虑模组化定价和服务模式，以降低初始采用门槛，并确保长期总拥有成本的可预测性。加强技术支援和培训计画可以减少分散式环境下的采用阻力，并增强临床医生的信心。最后，与公共卫生组织和参考网络建立策略合作伙伴关係，可以扩大监测范围，同时建构联合检验路径。透过协调产品蓝图、商业模式和强化业务永续营运措施，产业领导者将加速产品推广，同时降低短期市场波动。

本研究采用综合调查方法，结合一手访谈、二手文献回顾、资料三角验证与检验，确保研究结果严谨实用。

本报告的分析方法结合了结构化的初步研究、全面的二手文献综述和严谨的资料三角验证，以确保得出可靠且可操作的结论。初步研究包括对临床实验室主任、采购人员、医院管理人员和技术开发人员进行深入访谈，以了解其营运实务和决策标准。二级资讯来源包括同行评审的临床研究、监管指南、技术白皮书和已发布的产品文檔，用于阐明性能特征和检验标准。

资料综合分析将访谈结果与已记录的检验资料和监管申报文件进行交叉比对，以识别一致的主题和差距。调查方法采用情境分析，探讨不同临床和政策条件下的供应链敏感度和实施路径。品质保证流程包括多轮同侪审查和内部一致性检查，以确保结论的可靠性，并透明地揭露限制。在适当情况下，也提供了关于普遍适用性和本地适用性的考量，以帮助读者在其自身营运环境中解读研究结果。

透过全面的综合分析，为综合征检测中的业务决策提供支持，提取对临床护理、营运和行业战略的关键启示。

摘要，急性护理中的综合征检测正从一项新兴技术转变为一项可操作的实践，为快速临床决策、感染控制和公共卫生监测奠定基础。技术的成熟、医疗服务模式的转变以及政策环境的演变共同推动了该技术的普及应用，而供应链和贸易趋势则凸显了韧性和多样化筹资策略的重要性。细分市场分析表明，不同应用领域的临床优先事项各不相同。神经系统急症需要快速灵敏的检测，而呼吸系统疾病的激增则需要可扩展的检测能力和灵活的检测组合，这就需要采用适应性强的采购和检验方法。

展望未来，能够将技术互通性、稳健的服务模式和实证实施方案结合的相关人员，将更有可能获得最大的临床和营运效益。对本地製造、灵活的商业性交付以及与公共卫生和学术机构的伙伴关係进行策略性投资，将进一步提升系统的就绪度。最终，那些能够将产品设计与实际工作流程相结合并展现出可衡量的临床影响的机构，将主导向更快速、数据驱动的急诊诊断模式的转变。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 急诊越来越多采用多重PCR呼吸道病原体快速鑑定检测板
  • 透过将人工智慧驱动的演算法与综合征检测平台结合，加速诊断和预测分析
  • 扩大综合症检测范围，纳入医院抗菌药物管理中新出现的抗菌药物抗药性标记物
  • 监管和报销政策的变化影响着急性护理机构中照护现场分子综合症检测的采用。
  • 扩大次世代定序在医院症候群监测的应用，可以更快发现微生物集体爆发。
  • 供应商整合和策略联盟正在推动多种急诊护理检测的标准化和成本效益。
  • 整合数位健康平台的进步使得医院网路之间能够即时共用综合征数据。
  • 为了在急诊护理中实现快速决策，分散式照护现场分子诊断正日益普及。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按综合征和检测组别分類的急性护理综合征检测市场

  • 中枢神经系统
    • 脑炎
    • 脑膜炎
  • 消化器官系统
    • 细菌
    • 寄生虫
    • 病毒性的
  • 呼吸系统
    • 细菌
    • 合成的
    • 病毒性的
  • 性行为感染传染病
    • 披衣菌感染和感染疾病
    • 疱疹

9. 按产品类型分類的急性护理症候群检测市场

  • 装置
    • 工作台
    • 护理点
  • 试剂套件试剂
    • 墨水匣
    • 多重检测试剂套件
    • 试剂
  • 软体服务
    • 资料管理
    • 服务协定

第十章 依最终使用者分類的急性照护症候群检测市场

  • 学术研究机构
  • 医院
  • 公共卫生研究所
  • 参考检验机构

第十一章 按技术分類的急性护理症候群检测市场

  • 质谱分析
  • 微阵列
  • 多重PCR
  • 次世代定序
  • 定量PCR

第十二章 按应用分類的急性照护症候群检测市场

  • 鑑别诊断
  • 流行病学
  • 疫情调查
  • 研究
  • 监视

第十三章 各地区急性照护症候群检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 急性照护症候群检测市场（依组别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国急性照护症候群检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • bioMerieux SA
    • Cepheid, Inc.
    • Roche Holding AG
    • QIAGEN NV
    • Luminex Corporation
    • Becton Dickinson and Company
    • Hologic, Inc.
    • Seegene, Inc.
    • Quidel Corporation
    • Abbott Laboratories
Product Code: MRR-5A3042B3D68E

The Acute Care Syndromic Testing Market is projected to grow by USD 8.19 billion at a CAGR of 10.27% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.74 billion
Estimated Year [2025] USD 4.12 billion
Forecast Year [2032] USD 8.19 billion
CAGR (%) 10.27%

A concise introduction to the shifting paradigm in acute care syndromic testing, highlighting clinical integration, diagnostic speed, and system resilience

The landscape of acute care syndromic testing is experiencing a rapid and sustained evolution driven by technological advances, shifting clinical workflows, and heightened expectations for diagnostic speed and precision. Syndromic testing, which enables simultaneous detection of multiple pathogen classes, is increasingly embedded into urgent care and hospital settings where time-sensitive decisions can materially affect patient outcomes. As clinical teams seek to shorten diagnostic windows and reduce empiric therapy reliance, diagnostic platforms that integrate seamlessly with care pathways are moving from proof-of-concept to operational necessity.

Moreover, the interplay between laboratory infrastructure and point-of-care capabilities is reshaping procurement priorities. Healthcare administrators are balancing the need for high-throughput centralized testing with decentralized solutions that deliver actionable results close to the bedside. In parallel, public health authorities and infection prevention teams are leveraging syndromic data to support surveillance and outbreak response, further emphasizing the role of diagnostics in broader population health strategies. Consequently, stakeholders across clinical, operational, and commercial functions must align around real-world performance, interoperability, and the ability to demonstrate clinical utility within constrained budgets.

Transformative technological, regulatory, and care-delivery shifts reshaping syndromic testing pathways and accelerating point-of-care diagnostics adoption across institutions

Transformative shifts are converging to redefine how syndromic testing is developed, adopted, and sustained in acute care settings. Technological innovations such as highly multiplexed assays, integrated sample-to-answer platforms, and advanced data management capabilities are lowering barriers to rapid diagnosis. These technologies are complemented by improvements in assay design that increase pathogen breadth while preserving analytical sensitivity and specificity, which in turn expands clinical use cases beyond traditional respiratory panels into neurological, gastrointestinal, and sexually transmitted infection applications.

Concurrently, care-delivery models are adapting; emergency departments, intensive care units, and outpatient urgent care centers are demanding faster turnarounds and simplified workflows that reduce dependency on specialized laboratory staff. Regulatory landscapes and reimbursement frameworks are also evolving, encouraging faster adoption when clinical value can be demonstrated through outcomes, antibiotic stewardship, and reduced length of stay. Finally, digital connectivity and analytics are enabling near-real-time aggregation of syndromic results, creating opportunities for improved institutional surveillance and cross-institutional public health signal detection. Taken together, these shifts are accelerating the translation of syndromic testing from niche diagnostic aid to an essential element of acute care management.

Assessing the multifaceted consequences of United States tariff adjustments in 2025 on supply chains, device sourcing, manufacturing incentives, and clinical operations

Adjustments to tariff policies in the United States during 2025 introduced renewed considerations for manufacturers, distributors, and healthcare providers involved with syndromic testing. Supply chains that had been optimized for just-in-time inventory were forced to re-evaluate sourcing strategies as import costs and lead-time uncertainty increased. In response, many device and reagent suppliers accelerated diversification of vendor networks and explored regional manufacturing and assembly options to mitigate exposure to import volatility.

Consequently, procurement teams in hospitals and reference laboratories instituted more stringent supplier risk assessments and prioritized long-term supply agreements that provided greater transparency around capacity and contingency planning. For platform manufacturers, the tariff environment prompted reassessment of pricing structures and total cost of ownership models that account for logistics, customs delays, and inventory carrying costs. Over time, these adjustments influenced product roadmaps and capital allocation decisions, encouraging investments in modular designs and interchangeable consumables that reduce dependency on single-source components.

Importantly, clinical operations experienced transitional friction as lead-time variability affected kit availability for high-demand panels. In response, laboratories expanded validation of alternative assays and intensified collaboration with clinical stakeholders to prioritize testing based on acuity and infection control imperatives. Through these adaptations, the sector demonstrated resilience, but the tariff-induced disruptions underscored the strategic importance of supply chain transparency, manufacturing agility, and proactive stakeholder communication.

Insightful segmentation analysis revealing how panels, product types, end users, technologies, and applications drive adoption patterns and procurement decisions in acute care

A nuanced understanding of segmentation dynamics is essential to appreciate where demand will concentrate and how procurement choices will evolve. When testing is considered by syndromic panel, the central nervous system category, with its encephalitis and meningitis subgroups, prioritizes high analytical sensitivity and rapid turnaround due to the critical nature of neurological infections; gastrointestinal panels that distinguish bacterial, parasitic, and viral etiologies demand robust multiplex capability and specimen versatility; respiratory panels categorized across bacterial, combined, and viral targets must balance breadth with throughput to serve seasonal surges; and sexually transmitted infection panels that profile chlamydia, gonorrhea, and herpes require assays optimized for diverse specimen types and high specificity.

From a product-type perspective, instruments-ranging from benchtop analyzers to point-of-care devices-drive capital planning and lab footprint decisions, while kits and reagents including cartridges, multiplex assay kits, and standalone reagents underpin recurring revenue and supply continuity considerations; software and services focused on data management and service contracts are increasingly decisive for long-term total cost and operational efficiency. End-user segmentation clarifies adoption pathways: academic research institutes prioritize assay flexibility and depth for translational work, hospitals require validated workflows and rapid clinical reporting, public health laboratories emphasize surveillance compatibility and high-throughput capacity, and reference laboratories focus on scale and assay multiplexing to serve broad client networks. Technology choices also shape strategy: options such as mass spectrometry, microarray, multiplex PCR, next-generation sequencing, and qPCR each present distinct trade-offs in throughput, breadth, and turn-around time. Finally, applications including differential diagnosis, epidemiology, outbreak investigation, research, and surveillance determine performance requirements and the degree of integration with clinical and public health information systems. Collectively, these segmentation axes inform procurement prioritization, validation strategies, and partnership models across stakeholders.

Regional dynamics and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence deployment and support of syndromic testing programs

Regional dynamics materially influence deployment strategies, regulatory alignment, and support infrastructures for syndromic testing programs. In the Americas, incentives for point-of-care expansion and integrated electronic health record connectivity are shaping hospital and outpatient adoption, while regional supply chain hubs and manufacturing capacity support responsive replenishment. Across Europe, the Middle East & Africa, diverse regulatory frameworks and heterogeneous reimbursement environments necessitate differentiated commercialization approaches, as well as tailored service models that account for variable laboratory consolidation and centralization trends. In the Asia-Pacific region, rapid capacity expansion, localized manufacturing investments, and strong public health surveillance priorities have accelerated adoption of both high-throughput and decentralized platforms.

These regional distinctions affect not only where technologies are adopted but how companies structure market entry and post-sale support. For instance, service contracts and local technical support are critical in regions with limited on-site technical expertise, whereas software interoperability and data-sharing standards are prioritized in systems with advanced digital health infrastructures. Moreover, procurement cycles and capital allocation differ across regions, influencing the pace of roll-out for new panels and platform upgrades. Understanding these geographic nuances enables planners to align distribution strategies, local partnerships, and training programs to regional expectations and operational realities.

Competitive landscape and company-level strategies shaping innovation, partnerships, and commercialization in the acute care syndromic testing ecosystem

Corporate strategies within the syndromic testing ecosystem are evolving along multiple vectors, including platform differentiation, vertical integration of consumables, and strategic partnerships with laboratory networks and health systems. Manufacturers focus on delivering end-to-end solutions that minimize hands-on time, reduce failure points, and provide seamless connectivity to laboratory information systems and electronic medical records. At the same time, firms are investing in consumable portfolios that support recurring revenue while designing instruments with modularity to protect customers against obsolescence.

Partnerships and consortium models are emerging as a way to accelerate market penetration and validate clinical utility across diverse care settings. Companies are increasingly collaborating with academic centers for clinical validation studies and with public health agencies to align reporting formats and surveillance use cases. Competitive dynamics are also influenced by service models, as rapid-response technical support and managed inventory programs become differentiators in procurement decisions. Overall, the marketplace favors organizations that can combine robust analytical performance with strong post-sale support, clear integration pathways, and flexible commercial terms that accommodate varied end-user needs.

Actionable strategic recommendations for industry leaders to optimize supply resilience, accelerate clinical adoption, and align commercial models with healthcare priorities

Industry leaders seeking to secure sustainable advantage should prioritize a set of integrated actions that address technology, supply chain, clinical adoption, and commercial alignment. First, investing in platform interoperability and open data standards will accelerate clinical integration and enable downstream analytics that demonstrate value. Second, diversifying manufacturing and logistics partners while building regional distribution contingencies will minimize the operational impact of trade disruptions and customs variability. Third, embedding clinical evidence generation into commercial rollouts-through real-world evidence studies and stewardship-focused pilots-will strengthen adoption and payer conversations.

Additionally, executives should consider modular pricing and service models that lower barriers to initial deployment and offer predictable total cost of ownership over time. Strengthening technical support and training programs will reduce implementation friction and improve clinician confidence in decentralized settings. Finally, cultivating strategic partnerships with public health institutions and reference networks can expand surveillance reach while creating shared validation pathways. By aligning product roadmaps, commercial models, and operational resilience initiatives, industry leaders can accelerate adoption while mitigating near-term market volatility.

Comprehensive research methodology integrating primary interviews, secondary literature, data triangulation, and validation to ensure rigorous and actionable insights

The analytical approach underpinning this report combined structured primary research, exhaustive secondary literature review, and rigorous data triangulation to ensure reliable and actionable findings. Primary research included in-depth interviews with clinical laboratory directors, procurement leads, hospital administrators, and technology developers to capture operational realities and decision-making criteria. Secondary sources comprised peer-reviewed clinical studies, regulatory guidance, technology white papers, and publicly available product documentation to contextualize performance characteristics and validation standards.

Data integration involved cross-checking interview insights against documented validation data and regulatory filings, enabling identification of consistent themes and divergence points. The methodology incorporated scenario analysis to explore supply chain sensitivities and adoption pathways under varying clinical and policy conditions. Quality assurance steps included multiple rounds of expert review and internal consistency checks to ensure that conclusions were robust and that limitations were transparently acknowledged. Where relevant, caveats around generalizability and regional applicability were stated to help readers interpret findings within their operational context.

Concluding synthesis that distills key implications for clinical care, operations, and industry strategy to inform executive decision-making in syndromic testing

In summary, syndromic testing in acute care is transitioning from emerging capability to an operational cornerstone of rapid clinical decision-making, infection control, and public health surveillance. Technological maturation, shifting care delivery models, and evolving policy contexts are collectively driving broader adoption, while supply chain and trade dynamics highlight the importance of resilience and diverse sourcing strategies. Segmentation analyses make clear that clinical priorities differ by application area-neurological emergencies require rapid, high-sensitivity assays while respiratory surges demand scalable throughput and flexible panel composition-necessitating tailored procurement and validation approaches.

Looking forward, stakeholders who combine technological interoperability, robust service models, and evidence-driven adoption programs will be best positioned to capture clinical and operational benefits. Strategic investments in localized manufacturing, flexible commercial offerings, and partnerships with public health and academic institutions will further enhance system preparedness. Ultimately, the organizations that align product design with real-world workflows and demonstrate measurable clinical impact will lead the transition toward more responsive, data-informed acute care diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of multiplex PCR respiratory panels for rapid pathogen identification in emergency departments
  • 5.2. Integration of AI-driven algorithms with syndromic testing platforms to accelerate diagnosis and predictive analytics
  • 5.3. Expansion of syndromic testing panels to include emerging antimicrobial resistance markers for hospital stewardship
  • 5.4. Regulatory and reimbursement shifts influencing adoption of point-of-care molecular syndromic tests in acute settings
  • 5.5. Increasing use of next-generation sequencing in hospital syndromic surveillance to detect microbial outbreaks faster
  • 5.6. Vendor consolidation and strategic partnerships driving standardization and cost efficiencies in multiplex acute care testing
  • 5.7. Advancements in integrated digital health platforms enabling real-time syndromic data sharing across hospital networks
  • 5.8. Shift toward decentralized point-of-care molecular diagnostics to reduce time to actionable acute care decisions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Care Syndromic Testing Market, by Syndromic Panel

  • 8.1. Central Nervous System
    • 8.1.1. Encephalitis
    • 8.1.2. Meningitis
  • 8.2. Gastrointestinal
    • 8.2.1. Bacterial
    • 8.2.2. Parasitic
    • 8.2.3. Viral
  • 8.3. Respiratory
    • 8.3.1. Bacterial
    • 8.3.2. Combined
    • 8.3.3. Viral
  • 8.4. Sexually Transmitted Infection
    • 8.4.1. Chlamydia Gonorrhea
    • 8.4.2. Herpes

9. Acute Care Syndromic Testing Market, by Product Type

  • 9.1. Instruments
    • 9.1.1. Benchtop
    • 9.1.2. Point Of Care
  • 9.2. Kits Reagents
    • 9.2.1. Cartridges
    • 9.2.2. Multiplex Assay Kits
    • 9.2.3. Reagents
  • 9.3. Software Services
    • 9.3.1. Data Management
    • 9.3.2. Service Contracts

10. Acute Care Syndromic Testing Market, by End User

  • 10.1. Academic Research Institutes
  • 10.2. Hospitals
  • 10.3. Public Health Laboratories
  • 10.4. Reference Laboratories

11. Acute Care Syndromic Testing Market, by Technology

  • 11.1. Mass Spectrometry
  • 11.2. Microarray
  • 11.3. Multiplex Pcr
  • 11.4. Ngs
  • 11.5. Qpcr

12. Acute Care Syndromic Testing Market, by Application

  • 12.1. Differential Diagnosis
  • 12.2. Epidemiology
  • 12.3. Outbreak Investigation
  • 12.4. Research
  • 12.5. Surveillance

13. Acute Care Syndromic Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Acute Care Syndromic Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Acute Care Syndromic Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. bioMerieux SA
    • 16.3.2. Cepheid, Inc.
    • 16.3.3. Roche Holding AG
    • 16.3.4. QIAGEN N.V.
    • 16.3.5. Luminex Corporation
    • 16.3.6. Becton Dickinson and Company
    • 16.3.7. Hologic, Inc.
    • 16.3.8. Seegene, Inc.
    • 16.3.9. Quidel Corporation
    • 16.3.10. Abbott Laboratories

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ACUTE CARE SYNDROMIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ACUTE CARE SYNDROMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ACUTE CARE SYNDROMIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY